The U.S government’s first look at the real-world use of COVID-19 vaccines found their effectiveness…
View More COVID vaccine found highly effective in real-world US study
Home »
Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305
STAMFORD, Conn., Dec. 21, 2018 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company…
View More Loxo Oncology Announces Initiation of Phase 1/2 Clinical Trial for Highly Selective, Non-Covalent BTK Inhibitor, LOXO-305